Eli Lilly’s anti-amyloid drug donanemab, marketed as Lormalzi, has received regulatory approval in India, offering a new treatment pathway for patients with early symptomatic Alzheimer’s disease. Despite its potential to slow cognitive decline, neurologists, including Dr. Sudhir Kumar of Apollo Hospitals Hyderabad, warn that high costs, diagnostic barriers, and modest clinical benefits may limit its real-world adoption across the country.
How does donanemab work to treat Alzheimer’s?
Donanemab functions by clearing amyloid plaques, which are protein clusters that form in the brains of individuals with Alzheimer’s disease. According to Eli Lilly, the drug is specifically indicated for patients experiencing mild cognitive impairment or mild dementia. In the Phase III TRAILBLAZER-ALZ 2 clinical trial, the therapy demonstrated a roughly 35% reduction in the rate of cognitive and functional decline among participants. This mechanism represents a shift from traditional treatments that only manage symptoms to newer therapies intended to alter the underlying progression of the neuro-degenerative condition.
Dementia affects approximately 8.8 million people in India. Alzheimer’s disease accounts for the majority of these cases, making the development of disease-modifying therapies a significant area of focus for the medical community.
What are the primary concerns for Indian patients?
Medical professionals highlight several hurdles that could restrict the use of donanemab. Dr. Sudhir Kumar notes that the 35% slowing of decline should not be mistaken for a 35% improvement in memory. Patients will likely continue to experience cognitive regression, albeit at a slower pace. Furthermore, the treatment requires specialized monitoring to manage potential side effects. These clinical requirements, combined with the high cost of the drug, create a significant barrier for the average patient in India. The European Medicines Agency (EMA) previously expressed caution regarding the drug’s benefit-risk profile, eventually limiting its approval to a specific patient subgroup to minimize the risk of serious adverse reactions.
Is early diagnosis the key to treatment success?
Early diagnosis is essential because donanemab is only approved for those in the early stages of the disease. Without timely detection, patients often miss the window of opportunity where the drug is most effective. Winselow Tucker, President and General Manager of Eli Lilly and Company (India), maintains that the company is confident in the drug’s benefit-risk profile, noting that independent regulators conducted thorough reviews of the clinical data before granting approval. For families, the value of the drug may depend on whether it successfully preserves the patient’s independence for a longer period, even if the overall decline is not fully halted.
Pro Tip: Monitoring Cognitive Changes
If you or a loved one are concerned about memory loss, consult a neurologist early. Early screening can help differentiate between normal aging and signs of dementia, which is critical for accessing newer, specialized treatments.
Frequently Asked Questions
- Is donanemab a cure for Alzheimer’s? No. It is a disease-modifying therapy designed to slow the progression of cognitive decline in early-stage patients, not a cure.
- Who is eligible for donanemab? The drug is currently indicated for patients with mild cognitive impairment or mild Alzheimer’s disease.
- Why was there hesitation from international regulators? The EMA initially raised concerns about the balance between the drug’s clinical benefits and potential side effects before later approving it for a more restricted patient group.
- What does “35% slower decline” mean? It means that, on average, patients treated with the drug experienced a slower rate of worsening compared to those who did not receive the treatment.
Are you interested in learning more about advancements in neurodegenerative care? Subscribe to our newsletter for the latest updates on medical research and health policy in India.
